The American Food and Drug Administration (FDA) has recognised the FAMHP as its Belgian counterpart under the mutual recognition agreement (MRA) between the European Union and the United States.
Until today, the good manufacturing practices (GMP) for medicinal products were only available in English. As of now, the GMP will be available in French and Dutch on the FAMHP website.
Give your opinion on a clinical trial with genetically modified vaccines developed for the treatment of hepatitis B
The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial with the genetically modified hepatitis B vaccines from the company GlaxoSmithKline Biologicals. The purpose of this trial is to evaluate the safety, the immunogenicity and the efficacy of hepatitis B candidate vaccines in adult patients with chronic hepatitis B. The public consultation runs from 24 July 2018 to 23 August 2018 inclusive.
The AFMPS has created an online database to hold information on all the clinical trials that it approves in Belgium and that have not yet been concluded. Healthcare professionals and patients will be able to use the database to query recruitment criteria of the clinical trials.
New online database containing all medicinal products for human and veterinary use authorised in Belgium
The FAMHP publishes a new version of the medicinal product database containing all medicinal products for human and veterinary use authorised in Belgium. You can also find information about the availability or temporary supply problems of medicinal products.
At federal level, the authorities concerned, including the FAMHP, are launching a new information campaign on nuclear risk, coordinated by the FPS Interior.